Inventor · disambiguated record
Jesper Worm
Also filed as: WORM JESPER
10 granted patents·13 pending applications·69 citations·filing 2008–2025
86Inventor score
Files withHOFFMANN LA ROCHE8WORM JESPER6ENZON PHARMACEUTICALS INC3ROCHE INNOVATION CT COPENHAGEN AS3SANTARIS PHARMA AS2
Top patents by PatentIndex Score
23 records- 0194US8450290B2Methods for treating androgen receptor dependent disorders including cancersWORM JESPER·Filed 2010·Granted May 28, 2013·35 cites·8 claims
- 0289US7737125B2LNA antagonists targeting the androgen receptorENZON PHARAMACEUTICALS INC·Filed 2008·Granted Jun 15, 2010·27 cites·11 claims
- 0378US8492357B2Micro-RNA mediated modulation of colony stimulating factorsWORM JESPER·Filed 2009·Granted Jul 23, 2013·4 cites·16 claims
- 0475US2025136984A1Oligonucleotide agonists targeting progranulinHOFFMANN LA ROCHE·Filed 2024·Application pending·0 cites
- 0574US7989429B2LNA antagonists targeting the androgen receptorENZON PHARMACEUTICALS INC·Filed 2010·Granted Aug 2, 2011·2 cites·10 claims
- 0674US7915401B2Compounds for the modulation of beta-catenin expressionENZON PHARMACEUTICALS INC·Filed 2009·Granted Mar 29, 2011·1 cites·5 claims
- 0770US2025346894A2Antisense Oligonucleotide for Targeting ProgranulinHOFFMANN LA ROCHE·Filed 2024·Application pending·0 cites
- 0867US2025034576A1Double Stranded Oligonucleotide For Modulating JAK1 ExpressionHOFFMANN LA ROCHE·Filed 2024·Application pending·0 cites
- 0967US2023287412A1Oligonucleotide Agonists Targeting ProgranulinHOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 1065US12203071B2Oligonucleotide agonists targeting progranulinHOFFMANN LA ROCHE·Filed 2021·Granted Jan 21, 2025·0 cites·15 claims
- 1165US12104153B2Antisense oligonucleotide for targeting progranulinHOFFMANN LA ROCHE·Filed 2021·Granted Oct 1, 2024·0 cites·10 claims
- 1264US2009005335A1Compounds for the modulation of beta-catenin expressionSANTARIS PHARMA AS·Filed 2008·Application pending·0 cites
- 1362US2023002762A1Oligonucleotides comprising a phosphorodithioate internucleoside linkageROCHE INNOVATION CT COPENHAGEN AS·Filed 2022·Application pending·0 cites
- 1460US2025361507A2Antisense oligonucleotides for targeting progranulinWORM JESPER·Filed 2024·Application pending·0 cites
- 1558US8440809B2RNA antagonists targeting Hsp27WORM JESPER·Filed 2009·Granted May 14, 2013·0 cites·12 claims
- 1658US2014031409A1Methods for treating androgen receptor dependent disorders including cancersSANTARIS PHARMA AS·Filed 2013·Application pending·0 cites
- 1756US2012004288A1Compounds for the modulation of beta-catenin expressionWORM JESPER·Filed 2011·Application pending·0 cites
- 1854US8039446B2Compounds for the modulation of beta-catenin expressionENZON PHARMACEUTICALS INC·Filed 2010·Granted Oct 18, 2011·0 cites·11 claims
- 1953US12421552B2MicroRNA-134 biomarkerROCHE INNOVATION CT COPENHAGEN AS·Filed 2021·Granted Sep 23, 2025·0 cites·10 claims
- 2053US2020339982A1Oligonucleotides comprising a phosphorodithioate internucleoside linkageROCHE INNOVATION CT COPENHAGEN AS·Filed 2018·Application pending·0 cites
- 2152US2022403388A1Oligonucleotide Progranulin AgonistsHOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 2250US2025250571A1Double-stranded rna molecule for administration to the eyeHOFFMANN LA ROCHE·Filed 2025·Application pending·0 cites
- 2348US2011319471A1Lna antagonists targeting the androgen receptorWORM JESPER·Filed 2011·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →